Phase II for BioGard
Thursday, 15 January, 2009
Melbourne company Immuron, formerly known as Anadis, announced its BioGard hyperimmune bovine colostrum product will be studied in a Phase II trial in early stage HIV patients.
BioGard contains anti-lipopolysaccharide antibodies to reduce microbial translocation and immune activation in the gut and other mucosal surfaces. The study will be conducted at Case Western Reserve University hospital in the US.
Last year, the company announced the product would be part of the multi-national Phase IV CORAL study, in conjunction with Merck’s new integrase inhibitor Isentress (raltegravir). That study is set to begin this month.
In addition, a new formulation containing antibodies against HIV envelope antigens will be undertaken by the University of Melbourne’s Associate Professor Damian Purcell, following a research grant awarded by the Department of Health and Ageing.
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
